Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C22H17FN3O2S |
Molar mass | 406.46 g·mol−1 |
3D model (JSmol) | |
| |
|
MK-4409 is an experimental drug which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 11 nM, and both analgesic and antiinflammatory effects in animal studies. It was studied for the treatment of neuropathic pain and progressed to early stage human clinical trials by 2009.[1][2]
YouTube Encyclopedic
-
1/5Views:5 5794 665117 4045 3759 512
-
Mind Control Victim Tells His Life Story MK ULTRA
-
1of2 Proof of The Stupidity & Brainwashing of The American People
-
Canon 2x and 1.4x Extenders Photography Gear Review
-
Mainstream Media Mind Control - MK Ultra still Exist. | Documentary
-
Primary Weapon Systems 762x39 Mk111 Mod2
Transcription
See also
References
- ^ Chobanian HR, Guo Y, Liu P, Chioda MD, Fung S, Lanza TJ, et al. (June 2014). "Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain". ACS Medicinal Chemistry Letters. 5 (6): 717–21. doi:10.1021/ml5001239. PMC 4060928. PMID 24944750.
- ^ Merck (15 October 2009). "Merck Pipeline, Oct 2009" (PDF). Merck. Archived from the original (PDF) on 20 October 2016. Retrieved 18 January 2016.
External links
- "MK 4409". Adis Insight. Springer Nature Switzerland AG.